Добавлены профессиональными переводчиками и компаниями и на основе веб-страниц и открытых баз переводов.
hipertenzija, ii tipo cukrinis diabetas ir nefropatija.
hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease.
ir su nefropatija susijęs ii tipo cukrinis diabetas.
significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects.
atsargumo dėlei tikagreloro nerekomenduojama vartoti šlapimo rūgšties sukelta nefropatija sergantiems pacientams.
as a precautionary measure, the use of ticagrelor in patients with uric acid nephropathy is discouraged.
todėl pacientams, sergantiems diabetine nefropatija, negalima kartu vartoti akf inhibitorių ir aiira.
ace inhibitors and arbs should therefore not be used concomitantly in patients with diabetic nephropathy (see section 4.4).
pacientams, sergantiems diabetine nefropatija, negalima kartu vartoti akf inhibitorių ir angiotenzino ii receptorių blokatorių.
ace-inhibitors and angiotensin ii receptor blockers should not be used concomitantly in patients with diabetic nephropathy.
va nephron- d tyrimas buvo atliekamas su pacientais, sergančiais 2 tipo cukriniu diabetu ir diabetine nefropatija.
va nephron-d was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
irbesartan bms poveikis nefropatija sergantiems pacientams buvo tiriamas dviejuose plataus masto tyrimuose, kuriuose dalyvavo 2 326 ii tipo diabetu sergantys pacientai.
for the treatment of kidney disease, irbesartan bms was studied in two large studies involving a total of 2,326 patients with type 2 diabetes.
26 tarp oportunistinių infekcijų yra su bk virusu susijusi nefropatija ir su jc virusu susijusi progresuojanti daugiažidininė leukoencefalopatija (pdl).
27 multifocal leukoencephalopathy (pml).
pacientams, sergantiems diabetine nefropatija, negalima kartu vartoti akf inhibitorių ir angiotenzino ii receptorių antagonistų (aiirb).
ace inhibitors and angiotensin ii receptor blockers (arbs) should not be used concomitantly in patients with diabetic nephropathy.
todėl pacientams, sergantiems diabetine nefropatija, negalima kartu vartoti akf inhibitorių ir angiotenzino ii receptorių blokatorių (aiirb).
ace inhibitors and angiotensin ii receptor blockers (arbs) should therefore not be used concomitantly in patients with diabetic nephropathy (see section 4.4).